How pharma could shift from curing disease to promoting healthy ageing through epigenetics, the microbiome and antimicrobial innovation.

Women’s health remains chronically underfunded, yet closing the gap could unlock huge value for women and the global economy.

Prof Alexander Egeberg, Vice President, Head of Global Medical Affairs, LEO Pharma, reveals how the company is tackling unmet needs in dermatology.

How can the pharmaceutical industry ‘Accelerate Action’ on gender parity this International Women’s Day? Find out now.

Find out what the Senior Vice President, EU & International, Rare Diseases, Chiesi Group, thinks the pharma industry should consider on Rare Disease Day.

Jaime Manzanera, EMEA Brand Director, Oncology, Eisai, shares his perspective on maximising ROI in pharmaceutical marketing and more.

Recall matters when it comes to medical content. Find out how knowledge can be better retained through interactive medical education.

Dr Matthew Hickling explores the science behind beauty, his role in aesthetics and the opportunities shaping the future of the field.

There are many pillars of medical affairs, but field teams are where the action happens. How do you build teams that deliver results?

Attention is the new currency in pharma marketing. With HCPs overwhelmed by information, delivering engaging content is crucial to standing out.

In the pharmaceutical industry, improving customer experience has become the goal, but it’s time to look at it in a new way.

Roxana Redis, Associate Science Director of Advanced Modalities, Charles River Laboratories, talks about the exciting field of RNA.

In the final quarter of the year, how can pharmaceutical teams make their final budget decisions count?

The former Baxter leader talks about the founding of Vantive, the challenges facing kidney patients, improving access to dialysis and more.

Ever wondered what one of the world’s top oncology leaders believes to be the next big thing in cancer care? Find out in our interview AstraZeneca’s Dr Sunil Verma.

What key compliance considerations should pharma companies keep in mind before releasing new research in the US market, and how can they avoid compliance pitfalls?

Video is a powerful tool because it extends the reach of a live event, but does a recording ever live up to the event itself? Enter 3D interactive video.

AI is becoming less of a buzzword for those in the pharma industry. For medical affairs teams, how will it transform the function’s future?

If you want to engage HCPs, you must deliver high-quality medical education. But are all companies taking advantage of interactive quizzes?

A US congress is the place to put your drug on the map, but is this landscape the home of great customer experience for HCPs?

In today’s fast-paced pharma industry, it is vital for companies to provide an excellent customer experience for healthcare professionals.

Hear from four pharma leaders on the benefits to employees and patients of workplaces that promote inclusivity for the LGBTQ+ community.

A 3D, interactive approach allows pharmaceutical companies to share the latest medical breakthroughs in a more dynamic and engaging way.

Dr Harmony Garges, talks to EMJ GOLD about her decision to join the pharmaceutical industry, treating children with HIV and her views on improving access to HIV treatment.

Learn about how 3D human technology offers pharmaceutical companies a fresh and exciting way to take medical education to new heights.

The journey from approval to patient can be convoluted. How can pharma teams communicate the latest advances to busy healthcare professionals?

Stefan Woxström, Senior Vice President Europe and Canada, AstraZeneca, talks about the need for future-proofing healthcare systems, incentivising innovation and reimbursement.

Finding a way to combat the negative effects of ageing could save healthcare systems millions. Learn whether ageing could be the next big pharma market to take the world by storm.

Robyn Widenmaier (GSK) and Tabetha Sundin (AstraZeneca) discuss whether bids to improve gender parity could be the ticket to change in women’s health.

A new generation of doctors is making their way into the workforce, but is the pharmaceutical industry ready to change its tactics to engage these younger HCPs?

The value of medical affairs is not up for debate, but are companies allocating enough time and resources to make it the strategic function it can be?

A deal ends months of wrangling between the UK government and the ABPI, but what will it mean for the industry and the UK’s bid to become a life sciences superpower?

With compliance and regulatory hoops to jump through, medical affairs teams can be reluctant to try new tactics. This roundtable uncovers their relationship with risk and asks what the future holds.

Peter Ahnesorg, Global Hematology Franchise Head, Roche, talks about his background in biochemistry, his hopes for the haematology space and his approach to leadership.

Discover the past and future of hematology. Uncover the challenges, advancements, and the industry’s commitment to patient well-being.

Read about the role the pharma industry can play in ensuring patients can access the right information about medical conditions and medicines.

Dr Andreas Konieczny, Vice President and Head of Medical Affairs Europe, ImmunoGen, talks to GOLD about moving from big pharma to biotech, his passion for oncology and lessons in leadership.

The Irish pharmaceutical sector is expanding. Read more about what is driving companies to channel investment into the Emerald Isle.

To mark World Heart Day 2023, how can the industry strike a balance between driving innovation and ensuring access to care for all?

How can companies best leverage their KOLs earlier in the product lifecycle, and how do KOLs themselves want to involved?

Medical affairs and sales teams have distinctly different roles, but aren’t they just two planets orbiting the same sun?

How can medical affairs achieve efficiencies by standardising and modernising its insight gathering processes?

As the UK PMCPA publishes its first social media guidance for pharmaceutical companies, what can they do to avoid traps when it comes to posting online?

The pharmaceutical industry is being urged to take action to bridge the access gap for women with gynaecological cancers, but what steps are needed to change the game?

Karen Pinachyan, Head of Medical Affairs for Europe, CSL Behring, talks to Isabel O’Brien about the power of personalised medicine, overhauling healthcare and why it is key to know your own mind

The Cannes Lions International Festival of Creativity is finished for another year, but how did the pharmaceutical industry perform?

This week (14-16 May) is National Women’s Health Week in the US. Read what the industry can do to close the gender health gap.

Lance Hill, CEO of Within3, talks to GOLD about the challenge of creating a market for their product and his personal and professional measures of success.

Marcel Gehrung, CEO and Co-Founder, Cyted, talks to Jade Williams about the greatest challenges facing his company.

GOLD talks to Stuart Peltz, CEO, PTC Therapeutics, about his company’s journey from a single lab to a multinational corporation.

Medical affairs must have its finger on the pulse of customer and patient preferences. Social listening is a key way for teams to keep up.

Sabine Hutchison, CEO, Seuss+, and Operating Board President, EMEA, The Healthcare Businesswomen’s Association, discusses the legislation, challenges and hopes for closing the pay gap in life sciences.

Pharma leader Emma Chaffin talks about leaving pharmacy for the pharma and a key challenge facing her function.

Synthetic data can streamline clinical trials and enable ideas to be tested without draining R&D budgets. Read more about pros and cons of this approach.

Explore the benefits of using agencies in pharma marketing and some of the reasons why creativity needs to be brought to the foreground.

Pharma is a popular destination for women entering the workforce, but how can the lack of representation at senior levels be addressed?

For pharma, building an ERG can be essential for inclusivity. Find out how to create a great one with these top tips.

Christi Shaw, former CEO, Kite Pharma, shares her thoughts on improving access to cell therapies and her motivations for working in oncology

Exploring the current state of the US pharmaceutical market, this article investigates the balance between innovation and access to care in the country.

Roche’s Davidek Herron offers his thoughts on the state of diversity, equity and inclusion in the pharma industry.

Despite continued advances in personalised medicine, there is still more to be done to encourage policy makers and payers to back these life-changing initiatives.

In 2021, the UK was named the sixth biggest pharmaceutical market, but it’s facing challenges to further growth. Read to find out more.

The future is brimming with possibilities for AI in healthcare, but eliminating bias is imperative, so where should pharma start?

AI holds buckets of potential for medical affairs teams, but it must be adopted considerately and correctly to meet their needs.

Pharma’s approach to customer experience could be improved with humanisation of digital touchpoints.

Novo Nordisk’s new obesity drug could be set to transform obesity care, but there’s much more that pharma can do to help.

GSK’s Judy Stewart discusses her ambition to work in pharmaceuticals and make a difference to public health, the vast GSK vaccine pipeline, leadership and the importance of work-life balance.

What are the generation differences in how HCPs want to talk to pharma? Three generations of doctors share their thoughts.

AstraZeneca’s Mina Makar talks about solving unmet needs and how to champion the patient perspective.

Many top pharma companies have cut their Twitter ad spend after the Eli Lilly scandal, but should they take a risk and return?

Roche’s Davidek Herron offers five top tips for pharma teams striving for omnichannel excellence.

How can pharma maximise the impact of key opinion leaders in the ever-evolving digital world?

Medical affairs is becoming increasingly complex, but industry-academia collaboration aims to tackle this head on.

The recent approval of lecanemab is a win for Alzheimer’s patients, but how can pharma ensure access?

Travel to Poland to discover the factors driving its pharmerging status and access to medicine challenges.

Explore the key trends and themes industry experts predict will be in store for pharma over the next 12 months.

Treatments for cancer are continuously advancing, but pharma must also focus on supporting patients’ mental health.

Pharma’s data lake is increasing in size. Read to find out how the industry can use it to its best advantage.

How can blockchain-based technology advance business development and investment?

5 minutes with Gen Li, President of clinical trial database company Phesi.

Pharma should double down on its patient centricity efforts to help tackle inequalities in 2023 and beyond, says Helena Beer.

A postcode can determine health outcomes more than genetics. How can pharma help to solve the postcode lottery?

Pharma endeavours to drive positive action from patient insights. Read to find out how they could improve their methodologies and outcomes.

RWD for rare diseases is scarce, but pharma can work to leverage existing processes and build trust to enhance the scope of available data.

Generics and biosimilars are crucial to healthcare worldwide, but there are challenges in getting these medicine to patients.

The challenges faced by the transgender community are vast, but pharma has the power to drive better health equity. Read more.

With Moderna pledging not to enforce its COVID-19 vaccine patent in 92 LMICs, a hub in South Africa is pushing ahead with replication. Read for more details.

The pandemic has exacerbated already troubling trends in the market access but has also created an opportunity for change in how drugs are priced and procured.

Pharma is making great strides in tackling climate change, but more needs to be done to meet net zero targets.

Why is the purpose and value of medical affairs sometimes poorly understood by the wider pharma organisation, and what can be done?

In his second column, Davidek Herron, Global Head of Digital, Roche, considers this year’s successes and challenges and looks ahead to 2023.

While technology advances and mindsets shift, will there be space and demand for the role of the pharma sales reps in future?

The Japanese pharma industry has many intricacies, so how can companies navigate the ups and downs?

Daiichi Sankyo’s Mary Pinder-Schenck speaks about the evolution she has witnessed in oncology throughout her career and what she predicts for the future of the field.

A new review has outlined 20 recommendations for how the UK can become a world leader in cannabinoid innovation. But is it possible?

The pharmaceutical industry has been trying to refine, reduce and replace animal testing for some time, but animal rights activists argue progress is too incremental.

The overturning of Roe v. Wade is impacting access to medical abortion, but in what ways is pharma trying to help?

Two US pricing experts dissect the implications of The Inflation Reduction for the pharma industry in this roundtable.

Landmark science has led to an inundation of new transformative therapies, but is the cell and gene market at the point of saturation?

What techniques can pharma companies adopt and adapt from the tech giants dominating the stage of modern-day innovation?

What drives Novartis Oncology’s Reshema Kemps-Polanco to succeed?

Five minutes with Anat Cohen-Dayag, CEO of clinical-stage drug discovery and development company Compugen.

After dizzying heights of investment during the pandemic, biotechs have observed a slump, but the future may look more promising.

AI is being implemented into drug development to free up time, money and manpower, but how can humans and computers work together?

In his first regular column for GOLD, Davidek Herron discusses digital transformation in pharma and pursuing operational excellence.

With opioid abuse showing little sign of abating, what role can pharma play in addressing the crisis?

Kenya is home to a budding pharma sector, but the country still faces access to medicine challenges. What are they, and how can pharma help?

Hear from two industry thought leaders to find out how the pharmaceutical industry is harnessing the COVID-19 to advance rather than derail their mission to improve female representation.

Clinical trials of the past struggled with patient enrolment and cost efficiency. What can the pharmaceutical industry learn to improve them?

In this roundtable, hear from two industry thought leaders who share their ideas on how to build synergy between pharma and patients.

What is it like to switch from medicine to MA, and are we about to see this spike in the wake of COVID-19?

With continued drive for equality across the pharma industry, the issue of parental leave is coming to the fore. But is the industry’s approach sufficiently transparent, and what more can be done?

How can pharma embrace post-conference momentum?

What is a digital twin and how do they benefit pharma?

How can pharma boost R&D efforts into women’s health issues?

Decentralised clinical trials are held in high regard in terms of climate impact, but are they as sustainable as they seem?

How can pharma tackle public mistrust in genomic medicine?

The pharmaceutical industry is a rich source of material for the small screen, but why is it framed as the perpetual bad boy?

How does a physician make a difference in medical affairs? Juby Jacob-Nara tells her story.

What lies in wait for pharma in the social media jungle?

Blockchain allow patients to own their data and better protects their personal information. How could it change the data landscape in pharma?

India, known by some as ‘the pharmacy of the world’, has a growing pharma reputation, but what has shaped this company’s ascension to pharmaceutical powerhouse status?

How can the industry empower MSLs as they do sales reps?

The Sunshine Rule swept away the clouds that cast shade over the pharmaceutical industry’s interactions with its customers, but what has been its impact five years on?

Sanofi’s Bill Sibold shares his tips on reducing time to market for pharmaceutical drugs, public perceptions of the industry after COVID-19 and more.

Are public-private partnerships set to be drivers of innovation across the pharmaceutical industry? Read to find out more.

Non-adherence to medication can be caused by a range of factors, including unconscious biases. How can pharma rework current models to ensure they are connecting with patients?

Read the article to find out what action the pharma industry has taken to help Ukraine during the conflict.

Antimicrobial resistance poses a significant threat to human health worldwide, with inconceivable consequences. Is pharma doing enough?

Claus Zieler, President of Established Markets at Astellas, speaks about the role leaders play in cultivating an enticing company culture

Brazil has consistently appeared in the top 10 global pharmaceutical markets over the last decade and is making steady progress.

The first-time launch landscape is growing. In an increasing number of cases, it’s emerging biopharma and biotech companies launching new drugs rather than established pharma giants leading the way.

Reverse mentoring challenges the status quo and flips traditional learning dynamics on their axis. This how-to guide deconstructs what must be considered when building a reverse mentoring scheme in pharma.

How can emergency measures be translated into permanent solutions to increase the power and number of these trials?

A highly-effective pharmacovigilance function is a rising value differentiator for pharmaceutical companies. Read to find out more about the challenges.

The pharmaceutical industry views itself as increasingly patient centric, but do two patient advocates agree? In this roundtable discussion, they consider what the industry is doing well, and their views on how it could improve further

John Wahba, Medical Head of the Global Digital Hub, GSK, talks about how collaboration and teamwork will drive change in pharma, his views on digital and omnichannel optimisation and his passion for patient empowerment

The ambition of the Healthcare Businesswomen’s Association is to drive change in diversity, equity and inclusion healthcare and life sciences. Read the article to find out how.

TikTok took younger generations by storm in 2021. Is it time for pharma to turn to the platform? Read the article to find out more.

While the pharma industry is far away from immersing patients and HCPs in an open world of role play games, extended use of gamification is certainly on the horizon. FInd out more.

Exploring the pharmaceutical landscape in South Africa, GOLD considers several areas that are shaping the nation’s role in the future of global pharmaceuticals

GOLD explores pharma’s future in the metaverse, untangling the good, the bad and the uncertainties. Find out more.

Davidek Herron, Global Head of Digital at Roche, speaks to Isabel O’Brien about the myths surrounding digital transformation and much more.

The FDA has released new guidance on the use of real-world data and real-world evidence in drug development.

GOLD reviews the pharma industry approach to organisational change, strategising tips to drive it from the top down or bottom up.

The pharmaceutical industry needs to help restoring pre-pandemic routine vaccination levels and protect populations worldwide.

Today is World Health Day, and to celebrate GOLD asked Claire Gillis, CEO, VMLY&R Health, to share her thoughts on using creativity to create better access to healthcare for all

Now that the world has had time to see the risks and rewards of ChatGPT, pharma industry must decide whether to take it or leave it. Read for more.

Digital therapeutics are making their way onto the main stage, and pharma should be taking note. What lies ahead for potential partnerships?

GOLD explores what the pharmaceutical industry’s future might look like with the adoption of blockchain technology within its key functions.

Technology has redefined the exchange of health information. Find out how the pharma industry can help patients build confidence about digital health tools.

Europe is a front runner for pharmaceutical research and thought leadership Find out in what measure this is translating into home-grown innovation.